Prostate cancer, especially in advanced stages such as castration-resistant prostate cancer, is challenging to treat. Traditional therapies targeting androgen receptor (AR) signaling have limited efficacy. In a recent study, Japanese researchers investigated the potential of azolato-bridged dinuclear platinum(II) complexes, particularly 5-H-Y, as promising alternatives. Their findings highlight the complex’s ability to inhibit AR signaling and induce cell death in prostate cancer cells, providing a new avenue for prostate cancer treatment.

Microbes living in our guts help us digest food by reshaping the bile acids that our livers produce for breaking down fats. It turns out that two of these microbially-modified bile acids may affect our risk — in opposite directions — for developing colon cancer.

            The link between these bile acids and colon cancer risk was recently uncovered as University of Wisconsin–Madison scientists sought to better understand the relationship between gut microbes and our bodies.

Scientists from RMIT University and the Doherty Institute have developed a new blood test that could screen cancer patients to help make their treatment safer and more effective.

About one in two Australians will be diagnosed with cancer by the age of 85.

Craniopharyngiomas are brain tumors that negatively impact the hormonal function of the nearby pituitary. The tumor location often prevents necessary surgical intervention. Alternative pharmacological therapy requires an in-depth understanding of the tumor molecular characteristics. To address this gap, researchers from Japan analyzed gene expression within individual tumor cells. This study reports the molecular features and interactions of tumor and immune cells associated with two craniopharyngioma subtypes that will help identify future targeted therapeutics.

POSTECH and Severance Yonsei Cancer Hospital collaborate to develop a high-performance photoacoustic endoscopy featuring a transparent ultrasound transducer.